← Evidence map

ArticleFrontiers in pharmacology2026

Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China.

Yingzhou Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China. | Socratic